Spinal muscular atrophy and school transitions
Part of Brain & nervous system clinical trials.
This study looks at how people with spinal muscular atrophy (a genetic condition that affects muscle strength) experience changes in school – like moving from primary to secondary school or starting college. If you take part, you'll answer a questionnaire about your experiences, which may help schools and support services improve how they help others.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a diagnosis of spinal muscular atrophy (types 1, 2, or 3) confirmed by genetic testing.
- You must be enrolled in education – this includes primary school, secondary school, or further education (such as college or sixth form).
- You need reliable internet access and a device like a smartphone, tablet, or computer to complete the questionnaire.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is looking for children and teens with spinal muscular atrophy (SMA) who are already on a treatment like Spinraza, Evrysdi, or Zolgensma. The goal is to understand different forms of SMA and how the treatment affects them over time.
This study collects health information from people with spinal muscular atrophy (SMA) over time to learn more about the disease and how to improve care. It may help researchers understand SMA better.
This study looks at how muscles work in children and young adults with spinal muscular atrophy (SMA) who are taking or starting SMN-directed therapies (like Evrysdi, Spinraza, or Zolgensma). It aims to understand the body's response to these treatments, which could help improve future care.
This is a long-term observation study that follows people affected by spinal muscular atrophy (SMA), people who carry the SMA gene but have no symptoms, and families of people with SMA. It helps researchers better understand SMA and related genetic status, which can support future treatment planning.
This study follows people with spinal muscular atrophy (SMA) who have a particular genetic change in the SMN1 gene. It compares long-term outcomes for those who do and do not receive disease-modifying treatments, to better understand what helps over time.
This trial is a registry that collects health information from people with spinal muscular atrophy (SMA). It helps researchers understand the condition better and may support future studies and treatments.
Hear when a new Spinal Muscular Atrophy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.